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Abstract The health and economic implications of
new imaging technologies are increasingly relevant
policy issues. Cardiac magnetic resonance imaging
(CMR) is currently not or not sufﬁciently reimbursed
in a number of countries including Germany, pre-
sumably because of a limited evidence base. It is
unknown, however, whether it can be effectively used
to facilitate medical decision-making and reduce
costs by serving as a gatekeeper to invasive coronary
angiography. We investigated whether the applica-
tion of CMR in patients suspected of having coronary
artery disease (CAD) reduces costs by averting
referrals to cardiac catheterization. We used propen-
sity score methods to match 218 patients from a CMR
registry to a previously studied cohort in which CMR
was demonstrated to reliably identify patients who
were low-risk for major cardiac events. Covariates
over which patients were matched included comor-
bidity proﬁles, demographics, CAD-related symp-
toms, and CAD risk as measured by Morise scores.
We determined the proportion of patients for whom
cardiac catheterization was deferred based upon
CMR ﬁndings. We then calculated the economic
effects of practice pattern changes using data on
cardiac catheterization and CMR costs. CMR reduced
the utilization of cardiac catheterization by 62.4%.
Based on estimated catheterization costs of € 619, the
utilization of CMR as a gatekeeper reduced per-
patient costs by a mean of € 90. Savings were realized
until CMR costs exceeded € 386. Cost savings were
greatest for patients at low-risk for CAD, as measured
by baseline Morise scores, but were present for all
Morise subgroups with the exception of patients at
the highest risk of CAD. CMR signiﬁcantly reduces
the utilization of cardiac catheterization in patients
suspected of having CAD. Per-patient savings range
from € 323 in patients at lowest risk of CAD to € 58
in patients at high-risk but not in the highest risk
stratum. Because a negative CMR evaluation has
high negative predictive value, its application as a
gatekeeper to cardiac catheterization should be fur-
ther explored as a treatment option.
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Introduction
Adenosine-stress cardiac magnetic resonance (CMR)
is an increasingly utilized technology in the non-
invasive evaluation of patients suspected of having
coronary artery disease (CAD). Several studies have
demonstrated that CMR accurately detects signiﬁcant
CAD and that normal adenosine stress CMR results
have high negative predict value [1–5]. However,
researchers have not evaluated the economic impli-
cations of employing the technology as a gatekeeper
to more expensive and invasive procedures such as
cardiac catheterization.
In 2008, approximately 852,000 cardiac catheter-
izations were performed in Germany, translating into
over € 500 million in reimbursement for that year
alone [6]. Clinicians and policymakers have raised
concerns about its optimal utilization, as 60–70% of
cardiac catheterization procedures yield negative
results, and the procedure exposes patients to mor-
bidities, including bleeding, radiation exposure, and
contrast nephropathy. The low yield of cardiac
catheterization was recently demonstrated in a study
of nearly 400,000 patients without known coronary
artery disease referred for elective catheterization.
Only approximately one-third of the population were
found to have obstructive coronary atherosclerosis
[7]. The cost-effectiveness of diagnostic cardiac
technologies is also an increasingly relevant policy
issue internationally [8–13]. This is further heightened
by the predictive power of less expensive technologies
such as CMR. With these concerns in mind, the setting
of these concerns, we performed a cost-analysis to
explore the economic implications of using CMR as a
decision-making instrument and gatekeeper to cardiac
catheterization in a German care setting.
Patients and methods
Study population
We constructed a registry of all consecutive patients
referred to our center for CMR evaluation within a
seven-month period in 2007 and 2008. For the current
analysis, our study group consisted of patients with
suspected CAD who were candidates for invasive
coronary angiography but ﬁrst underwent stress CMR
for further risk stratiﬁcation. We refer to this group as
the ‘‘Physician Gatekeeper’’ cohort, or PG. Data were
collected on comorbidities, demographics, CAD-
related symptoms, and CAD risk as measured by
Morise scores [14]. Patients were followed to deter-
mine whether they were subsequently referred to
cardiac catheterization after undergoing CMR.
Stress CMR exam
We considered exclusion criteria prior to perfor-
mance of CMR, including standard CMR contraindi-
cations such as the presence of an internal pacemaker
or deﬁbrillator, cerebral aneurysm clips, metal in the
eye, and contraindications to adenosine including
history of asthma or bronchospasm. All anti-anginal
medication and caffeinated beverages were stopped
at least 24 h prior to the CMR exam. Informed
consent was obtained from all patients. The protocol
was approved by the local ethics committee.
CMR studies were performed with a 1.5T mag-
netic resonance system (Signa Excite
, GE Health-
care Milwaukee, USA) using an 8-element phased
array surface coil (cardiac coil, GE Healthcare). In
patients with claustrophobia, mild sedation with
midazolame was offered. Cardiac function was
assessed at rest in 3 long (two-chamber, three-
chamber, and four-chamber) and contiguous short
axes using steady-state free precession sequences.
After infusing adenosine at a constant rate of
140 lg/kg per minute for 3 min (Spectris MR injec-
tor, Medrad, Indianola, USA), ﬁrst-pass kinetics of
a gadolinium-based contrast agent (Gadodiamide,
Omniscan
TM
, GE Healthcare Buchler, Germany;
0.1 mmol/kg) was measured during breath-hold in
4–5 contiguous short axis orientations at every heart
beat with a hybrid gradient echo/echo-planar pulse
sequence (echo time 1.2 ms, ﬂip angle 25, slice
thickness 8 mm, ﬁeld of view 32–34 9 24–25.5 cm,
matrix 128 9 96). This method has been described
previously [5, 15]. Ten minutes after stress perfusion,
a second perfusion in the same orientation and with
the same settings was performed at rest. Ten minutes
after this second bolus, late enhancement images were
acquired using an inversion-recovery prepared gated
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123fast-gradient echo-pulse sequence (repetition time
6.7 ms; echo time 3.3 ms; ﬂip 20; inversion time
individually adjusted; slice thickness 8 mm; rectan-
gular ﬁeld of view 30 to 34 cm; matrix 256 9 160).
As planned in the perfusion study, 4–5 short axes and
3 long and contiguous short axes views using a 3D 20
slice sequence were acquired.
Two experienced investigators evaluated all CMR
studies in consensus. Perfusion images were assessed
visually. A perfusion deﬁcit was regarded as relevant
if it affected[1/3 of myocardial wall thickness in C2
neighbouring segments, persisting [5 heart beats
after maximal signal intensity in the cavity of the left
ventricle (Fig. 1a and b). Late gadolinium enhance-
ment (LGE) images were analysed visually and bright
segments from subendocardial to epicardial were
classiﬁed as ﬁbrotic due to myocardial infarction
(Fig. 1c and d).
Analysis and statistical model
The CMR registry included 605 patients. We elim-
inated those who met contraindications for CMR. We
used propensity score methods [16] to match our
study population (PG) to a previously-studied cohort
in which CMR was demonstrated to reliably identify
patients who were low-risk for major cardiac events
(follow-up group, or FG) [5]. This control group
consisted of 218 patients suspected of having CAD
who were found to have a negative stress CMR. The
negative predictive value of CMR in this cohort was
99.1% and no patients experienced cardiac death,
myocardial infarction, or other major adverse cardiac
events (MACE) during a 12-month follow-up period.
Through close matching, this control group served as
a proxy for expected outcomes in our study cohort, as
long-term outcomes were otherwise unavailable.
Of the 605 patients in our original cohort, we
eliminated 181 patients who had indications for CMR
otherthanCADassessment(Fig. 2)and3patientswho
did not complete a full CMR exam. This left a sample
of 421 patients, compared to 218 patients in the FG
cohort.Aone-to-onepropensityscorematchwasused,
resulting in a ﬁnal matched sample of 218 PG patients.
Thisapproachwasusedtoensureasimilardistribution
of characteristics in the PG and FG cohorts. Matching
criteria included: age, gender, body mass index,
dyslipidemia, presence of diabetes, hypertension, and
smoking status. The matched PG and FG cohorts did
not differ signiﬁcantly across major characteristics,
including Morise score (P = 0.19) and other CAD
risk factors (P = 0.47). The residual sample of 203
patients had similar results to the primary PG cohort
but were not included in the analysis.
Fig. 1 Stress CMR—pathological ﬁndings. Short axis views
of a normal ﬁrst-pass perfusion under rest (a) but severe infero-
septal ischemia under adenosine-stress (b) and non-transmural
scar detection my means of LGE (c). Subsequent coronary
angiography revealed chronic occlusion of the right coronary
artery (d)
Fig. 2 Indications for CMR exams. Registry data on 605
consecutive patients
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We determined the portion of patients who were able
to avoid cardiac catheterization based upon CMR
ﬁndings. We then performed a cost analysis using
data on the costs of cardiac catheterization and CMR
and the portion of averted cardiac catheterizations.
Our analysis was performed from the payor perspec-
tive using 2009 data in Euros.
We estimated cardiac catheterization costs using
the difference in relative value units (RVUs) for a
hospitalization in Germany with and without cathe-
terization. We then multiplied this ﬁgure by € 2,800,
the average accepted multiplier cost for hospitaliza-
tions in Germany in 2009 [17]. This yielded a
catheterization cost of € 619. Please refer to the Sect.
‘‘Appendix’’ for further details.
Because CMR is not currently reimbursed in
Germany, we estimated its cost using the ratio of
CMR to catheterization cost from the Centers for
Medicare & Medicaid Services (CMS) in the United
States [18]. We then applied this ratio to our
catheterization cost to yield an estimated cost of
CMR of €296.
We performed an overall cost analysis across all
patients suspected of having CAD and sub-analyses
for patients with different pretest probabilities of
CAD, as determined by Morise scores. The sub-
analyses included the following Morise score cate-
gories: 0–4 (very low risk); 5–8 (low risk); 9–12 (low
intermediate risk); 13–15 (high intermediate risk);
16–18 (high risk); and [18 (very high risk). Sensi-
tivity analyses were performed on the cardiac cath-
eterization deterrent rates to evaluate the impact of
this key input on model results.
Results
Descriptive statistics
We enrolled 602 of 605 consecutive patients (99.5%)
scheduled to undergo stress CMR during a 7 month
enrollment period. Patients varied in speciﬁc indica-
tions for CMR referral but all ‘‘CAD gatekeeper’’
patients were thought to likely undergo catheteriza-
tion otherwise (Fig. 2).
Clinical characteristics of the matched PG and FG
cohorts are displayed in Table 1. These groups did
not differ signiﬁcantly by Morise score, CAD-related
symptoms, or other characteristics used in the
propensity score algorithm.
Catheterization avoidance rates
Patients who had preserved myocardial viability, as
demonstrated by the absence of LGE, and normal
CMR ﬁndings with ﬁrst-pass perfusion under both
rest and adenosine-stress experienced signiﬁcantly
lower rates of subsequent cardiac catheterization
(Fig. 3).
The portion of cardiac catheterizations averted as a
result of CMR ﬁndings is shown in Table 2. Sixty-
two percent of patients evaluated with CMR did not
undergo subsequent catheterization. This rate varied
by Morise score: patients with lower Morise scores
and lower pretest probability of CAD had higher
catheterization avoidance rates, while the opposite
was true for patients with higher pretest probabilities.
Net cost analysis
The results of the cost analysis are summarized in
Table 3. CMR is associated with average cost savings
of €90 per patient. These savings are inversely
correlated with baseline Morise score, with patients
with the lowest baseline risk of CAD realizing the
highest savings (€323). Moreover, cost savings were
realized for every Morise sub-group with the excep-
tion of the highest risk cohort (Morise score[18)
cohort, where costs increased.
Breakeven analysis
We performed breakeven analyses by varying CMR
cost and the portion of averted cardiac catheteriza-
tions to determine when CMR would be cost neutral.
This analysis demonstrated that the utilization of
CMR would continue to yield cost savings until its
cost exceeded €386 or its associated catheterization
diversion rates fell to 48% (Table 3).
Sensitivity analysis
The results of the sensitivity analysis are displayed in
Table 4. We varied the portion of averted cardiac
catheterizations, cost of cardiac catheterization, and
cost of CMR by 20% in both directions. We also
116 Int J Cardiovasc Imaging (2011) 27:113–121
123report the results of the sensitivity analyses across
Morise score subgroups. Cost savings remained
greatest for patients with lower Morise scores but
were present in most risk strata. However, for patients
with Morise scores greater than 16, using CMR as a
gatekeeper would increase total costs if catheteriza-
tion avoidance rates fell by 20% or the cost of
catheterization or CMR increased by 20%.
Fig. 3 Stress CMR—normal ﬁndings leading to catheteriza-
tion avoidance in a patient with pre-test risk and clinical
presentation comparable to the case in Fig. 1. Short axis views
of a normal ﬁrst-pass perfusion under both rest (a) and
adenosine-stress (b) and absence of LGE (c)
Table 1 Descriptive statistics
Variables Mean
a P value
b
Follow up Matched gatekeeper
N = 218 N = 218
Morise score 13.85 (3.8) 14.2 (3.0) 0.19
CAD-related clinical presentation 0.45
Anginal symptoms 69.7 % 64.7 %
Pathological stress test 3.7 % 5.5 %
Arrhythmia/risk factors 26.6 % 29.8 %
Angina CCS
c 1.79 (0.59) 1.77 (0.57) 0.72
Age 63.2 (12.9) 62.9 (13.7) 0.83
BMI 26.8 (4.6) 26.4 (4.7) 0.47
Male 56.0 % 55.1 % 0.85
Dyslipidemia 36.7 % 33.9 % 0.55
Diabetes 8.7 % 9.6 % 0.74
Hypertension 68.4 % 68.8 % 0.92
Smoker 35.3 % 34.4 % 0.84
 Systolic blood pressure[140 mm Hg and/or diastolic blood pressure[90 mm Hg
 Fasting plasma glucose of [126 mg/dl or 2-h postload glucose of [200 mg/dl or symptoms of diabetes mellitus and random
plasma concentration of[200 mg/dl
 Known total cholesterol[250 mg/dl or long-term treatment with a lipid-lowering agent
a Standard deviations are in parentheses for continuous variables
b Student’s t test for continuous variables and Chi-square test for binary variables
c in symptomatic patients
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Our study represents a preliminary investigation of
the potential cost savings associated with utilizing
CMR as a gatekeeper to invasive coronary angiog-
raphy [19]. Cardiac catheterization is an expensive
and invasive procedure, and major studies have
demonstrated that, in select populations of CAD, it
is not associated with an incremental survival beneﬁt
[20]. Moreover, the diagnostic yield of cardiac
catheterization in conﬁrming the presence of sus-
pected CAD is poor [7, 21, 22]. Finally, because
CMR evaluation has a high negative predictive value
for disease-free survival, its application as a gate-
keeper to cardiac catheterization should be further
explored as a policy option.
We found that the utilization of CMR substantially
reduced the need for cardiac catheterization in the
diagnostic CAD work-up and was cost-saving even at
reimbursement levels up to €386. Importantly, our
population was primarily comprised of patients who
would otherwise undergo cardiac catheterization, and
cost savings were present across patients across a
wide spectrum of pretest CAD risk. To our knowl-
edge, this is the ﬁrst documentation of the economic
impact of CMR in a ‘‘real world’’ registry.
Beyond serving as an effective gatekeeper to
cardiac catheterization, the utility of CMR as an
instrument for risk stratifying patients with suspected
CAD is also an important beneﬁt. Researchers have
demonstrated that a normal adenosine stress CMR
has high predictive value. In a study of 461 patients
with known or suspected CAD, Jahnke et al. found
that three-year event-free survival was 99.2% for
patients with a normal adenosine and dobutamine
stress CMR [4]. We have also previously shown that
a normal CMR is associated with a low MACE rate
and favourable one-year prognosis in 218 patients
with suspected CAD [5].
Table 2 Cardiac catheterization avoidance rates
COHORT Percent of CATHs avoided
All 62.4
Morise: 0–4 100.0
Morise: 5–8 85.7
Morise: 9–12 66.7
Morise: 13–15 64.1
Morise: 16–18 57.1
Morise:[18 47.1
Table 3 Net cost analysis*
COHORT Net cost savings
per patient (in €os)
All 90
Morise: 0–4 323
Morise: 5–8 235
Morise: 9–12 117
Morise: 13–15 101
Morise: 16–18 58
Morise:[18 -5
*Based on catheterization costs of €619 (see ‘‘Appendix’’ and
Lit 14) and CMR costs of €296 (see Lit 15)
Table 4 Sensitivity analysis
Model input ?20% -20%
CATH avoidance rate
All 167 13
Morise: 0–4 323 199
Morise: 5–8 323 128
Morise: 9–12 199 34
Morise: 13–15 180 22
Morise: 16–18 128 -16
Morise:[18 54 -63
CATH cost
All 167 13
Morise: 0–4 447 199
Morise: 5–8 341 128
Morise: 9–12 199 34
Morise: 13–15 180 22
Morise: 16–18 128 -16
Morise:[18 54 -63
CMR cost
All 30 149
Morise: 0–4 264 382
Morise: 5–8 175 294
Morise: 9–12 57 176
Morise: 13–15 42 160
Morise: 16–18 -2 117
Morise:[18 -64 55
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123Our results are similar to other studies evaluating
the utilization of non-invasive cardiac imaging tech-
nologies as gatekeepers to cardiac catheterization. In a
recent paper on the German pilot phase of the
EuroCMR registry, Bruder et al. reported that a
substantial proportion of patients (45%) did not
undergo invasive angiography due to a normal CMR
stress test [23]. The even higher overall catheter
avoidance rate in our study may be due either to
differences in patients’ pre-test risk, to the exclusive
use of adenosine stress in our center (higher negative
predictive values than for dobutamine stress [1]) or to
higher physicians’ adherence rates to CMR results
within a single-center setting. In our view, the latter
aspect relying on the high negative predictive value of
stress CMR in CAD evaluation deserves particular
attention in future studies and registries. Clearly,
physicians’ compliance with the gatekeeper approach
by waiving additional angiographies remains a
prerequisite for cost-effectiveness. Høilund-Carlsen
et al. found that single photon emission computed
tomography (SPECT) reduced the need for catheter-
ization by 50%. Even in high-risk groups, substantial
cost savings were attainable, and the risk of misiden-
tifying patients with severe disease was low [24].
Shaw et al. performed a study in which SPECT was
successfully used within a diagnostic pathway tar-
geted towards selective resource utilization. They
signiﬁcantly reduced referrals to cardiac catheteriza-
tion and attained cost savings by identifying low-risk
patients who beneﬁt from a more conservative care
approach [11]. However, SPECT exposes patients to
high doses of ionizing radiation, whereas CMR is a
safer procedure [25, 26].
Our study has several limitations. We used
matched populations to predict the risk of MACE in
patients with negative CMR studies, as we did not
have adequate follow-up in our study population. We
also did not compare CMR to other noninvasive
stress testing. As the sensitivity and speciﬁcity of
noninvasive cardiac imaging modalities varies, the
economic implication of their utilization as gatekeep-
ers will also be affected. Our cost inputs were also
associated with uncertainty, as CMR unit procedural
costs and cardiac catheterization costs vary geo-
graphically [27]. Our study population may also not
be representative of patients in other practice settings
or with different demographic proﬁles. Finally, our
analysis was performed from the payor perspective
and may not be relevant to policymakers concerned
with other perspectives such as the societal one.
Conclusion
CMR signiﬁcantly reduces the utilization of cardiac
catheterization in patients suspected of having CAD,
and patients with normal CMR results have a low-risk
of adverse cardiac events. We project that average
per-patient costs would fall by €90 if CMR were
routinely used as a gatekeeper to cardiac catheteri-
zation, and its application should be further explored
by researchers and policymakers.
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Appendix
Calculation of catheterization cost
Diagnostic catheterization costs within the German
DRG system (reimbursement for hospitals/inpatient
care) can be derived by comparing reimbursement for
coronary arteriosclerosis without (DRG F66B, 1 day
hospital stay) and with diagnostic catheterization
(DRG F49F, 1 day hospital stay). Taking €2800 as an
average ‘base case value’ for Germany this leads to
catheterization costs of €619 for the year 2009.
The relative value for invasive cardiac diagnostic
and 1 day hospital stay (DRG F49F) is 0.393.
The relative value for DRG F66B, major diagnos-
tic category for coronary arteriosclerosis without CC,
is 0.474. For 1 day stay this value needs to be
reduced by 0.302 which results in ﬁnal relative value
of 0.172.
Subtracting 0.172 from 0,393 yields 0.221, which
is our measure of the change in relative value due to
Int J Cardiovasc Imaging (2011) 27:113–121 119
123catheterization. Multiplying this difference, by the
average base case value for Germany €2,800), results
in €618.80 & €619.
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